Pharmacy Times

Pharmacy Times is a monthly magazine aimed at pharmacists, published by Intellisphere, LLC. It offers valuable clinical insights that pharmacists can apply in their daily work. Every issue includes articles and features on various topics such as pharmacy trends, medication mistakes, drug interactions, educating patients, pharmacy technology, managing diseases, counseling patients, updates on products, pharmacy regulations, and specialty pharmacy. The magazine is located in Plainsboro, New Jersey.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#120418

United States

#38079

Health/Health

#865

Traffic sources

Monthly visitors

Articles

Journavx From Vertex Pharmaceuticals Inc

3 days ago | pharmacytimes.com | Monica Holmberg

The FDA has approved suzetrigine oral tablets (Journavx; Vertex Pharmaceuticals Inc), a nonopioid oral pain signal inhibitor, for the treatment of moderate to severe acute pain in adults.1,2 Common causes of acute pain include accident, injury, or surgery.
Psilocybin, Ketamine, and MDMA in Cancer Care: Next Steps in Psychedelic Research

4 days ago | pharmacytimes.com | Manish Agrawal |Alana Hippensteele

CommentaryVideoJune 24, 2025Author(s):,Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety. As interest grows in the therapeutic potential of psychedelics, the role of pharmacists in ensuring safe, effective, and ethically sound care is becoming increasingly important.
Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

5 days ago | pharmacytimes.com | Alana Hippensteele

For oncology pharmacists, understanding the 505(b)(2) approval pathway and its implications is necessary to effectively navigate the challenges 505(b)(2) drugs are creating for infusion center pharmacies, explained Scott A. Soefje, PharmD, MBA, BCOP, during the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon.
Psychedelic Group Therapy Expands From Cancer Care to Treat PTSD in Active Duty Military

5 days ago | pharmacytimes.com | Manish Agrawal |Alana Hippensteele

CommentaryVideoJune 23, 2025Author(s):,Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation in military post-traumatic stress disorder (PTSD) research, the sustained benefits of long-term patient integration, and growing institutional interest in psychedelic-assisted therapy.
OPC 2025: Adapting Oncology Pharmacy to the Age of AI and Drug Shortages

1 week ago | pharmacytimes.com | Alana Hippensteele

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, several studies were presented that have direct implications for the role of oncology pharmacists in the cancer care team.
OPC 2025: Key Studies Shaping Lung Cancer Therapy From ASCO 2025

1 week ago | pharmacytimes.com | Alana Hippensteele

FeatureArticleJune 20, 2025Author(s):At the 2025 Oncology Pharmacists Connect (OPC) meeting, Kevin Chen, PharmD, MS, BCOP, CPP, reviewed several key studies from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting significant advancements in the treatment of small cell and non–small cell lung cancer.
Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

1 week ago | pharmacytimes.com | Luke Halpern

Author(s):The expansion of pneumococcal vaccine recommendations would ultimately lead to economic and health benefits, especially for underserved populations. Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period.
FDA Approves Dupilumb for Treatment of Bullous Pemphigoid

1 week ago | pharmacytimes.com | Aislinn Antrim

FDA officials approved dupilumab (Dupixent; Sanofi, Regeneron) for the treatment of adults with bullous pemphigoid (BP), marking the first and only targeted treatment for BP.1 The supplemental biologics license application was accepted by the FDA for priority review in February 2025.2BP is a chronic, debilitating, and relapsing skin condition with underlying type 2 inflammation.
Expert: Overcoming Challenges in CIDP Pharmacotherapy Management

1 week ago | pharmacytimes.com | Luke Halpern |Amy Duong

CommentaryVideoJune 20, 2025Author(s):,Amy Duong, PharmD, BCACP, highlights the importance of patient counseling and addressing logistical challenges in treating patients with chronic inflammatory demyelinating neuropathy (CIDP).
ADA 2025: Insights into Diabetes, Obesity, and Pharmacist's Role in Advancing Care

1 week ago | pharmacytimes.com | Kennedy Ferruggia |Diana Isaacs

CommentaryVideoJune 20, 2025Author(s):,Expert shares key upcoming sessions at the American Diabetes Association 85th Scientific Sessions. In an interview with Pharmacy Times®, Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, remote monitoring program coordinator and endocrinology clinical pharmacy specialist at the Cleveland Clinic, shares insights about the upcoming American Diabetes Association 85th Scientific Sessions.